VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma
- 27 July 2017
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (1)
Abstract
Background: The combination of vincristine, irinotecan, and temozolomide (VIT) is often used to treat children and adolescents with relapsed rhabdomyosarcoma (RMS); however, the outcome of these patients has not been previously described.Procedures: We sought to determine the response rate (RR) and progression‐free survival (PFS) for patients with relapsed RMS treated with VIT by retrospective review of patients treated at five tertiary care hospitals. Prior treatment with irinotecan was permitted.Results: Among 19 patients with a median age of 8 years (range 2–17 years), 12 (63%) were males and 12 (63%) had embryonal histology. Median time to relapse from initial diagnosis was 16 months (range 2.8‐45 months). VIT was used as first, second, third, or fourth line of therapy in four (21%), seven (37%), six (32%), and two (10%) patients, respectively. Four patients received VIT as adjuvant therapy following radiation and/or surgery. Therefore, among 15 evaluable patients, the best response to VIT was 0 (complete response, CR), 0 (partial response, PR), 4 (stable disease, SD), and 11 (progressive disease, PD) for an overall clinical benefit rate (CR + PR + SD) of 26.7% (95% CI: 7.8–55.1%). After a median follow‐up of 8 months, 2 (10%) patients were alive without disease, 3 (16%) were alive with disease, and 14 (74%) patients died of PD. PFS at 3 months was 23% (95% CI: 5.7–46.7%).Conclusions: VIT therapy in combination with adequate local control is associated with some disease control in patients with first relapse RMS and may be another reasonable option to offer patients as salvage therapy.Keywords
This publication has 19 references indexed in Scilit:
- Does surgery have a role in the treatment of local relapses of non‐metastatic rhabdomyosarcoma?Pediatric Blood & Cancer, 2011
- Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2010
- Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experiencePediatric Blood & Cancer, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology GroupJournal of Clinical Oncology, 2007
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcomaPediatric Blood & Cancer, 2005
- Temozolomide in resistant or relapsed pediatric solid tumorsPediatric Blood & Cancer, 2005
- Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children’s Oncology Group StudyJournal of Clinical Oncology, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958